Use of cell differentiation effectors to select a human B lymphoblastoid cell line enriched in C3b receptors.
A study was undertaken to establish conditions of growth to increase C3b receptor synthesis on a human B lymphoblastoid cell line (Raji) by use of cell differentiation effectors. It appears that whereas two polar compounds HMBA (2mM) and Me2SO(2%) have no or little effect, 5 BrdU (30microM) and db cAMP (5 x10(-4) M) are able to increase in 48 h and 36 h respectively the synthesis of C3b receptor on Raji cell surface. These two compounds help to select a variant in which 100% of cells have C3b receptors with a high density of receptors per cell. The mechanism of BrdU action on the regulation of C3b receptor synthesis is discussed.
D000081:Acetamides / Q000494:pharmacology; D001402:B-Lymphocytes / Q000276:immunology*; D001973:Bromodeoxyuridine / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D002460:Cell Line; D002469:Cell Separation; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D003179:Complement C3b / Q000096:biosynthesis*; D003959:Diamines / Q000494:pharmacology; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D011951:Receptors, Complement / Q000096:biosynthesis* / Q000187:drug effects
D000081:Acetamides; D003959:Diamines; D011951:Receptors, Complement; D003994:Bucladesine; D003179:Complement C3b; D001973:Bromodeoxyuridine; C014026:hexamethylene bisacetamide; D004121:Dimethyl Sulfoxide